Endocrine Abstracts

Objectives: To describe the prevalence of liver steatosis in a cohort of patients with Cushing’s disease.

Methods: Cross-sectional descriptive study. We included 59 patients with Cushing’s disease from our cohort of patients who underwent a Fibroscan to analyze the degree of hepatic steatosis (CAP measured in dB/m) and liver fibrosis (fibrosis measured in kPa). Biochemical algorithms of liver steatosis and fibrosis were assessed.

Results: 7 (11.9%) men and 52 (88.1%) women. Median age 52 [43–61] years with 9.3 [3.7–18] years of follow-up. 40 (67.8%) cured and 19 (32.2%) non-cured. Median years of hypercortisolism was 2.13 [0.76–5.17] years. 26 (44.1%) showed any pituitary defficiency, 18 (30.5%) ACTH defficiency, 7 (11.9%) sex hormones defficiency and 16 (27.6%) thyroid. Metabolic morbidities were, obesity in 29 (48.3%) patients, type 2 DM 16 (27.6%), HBP 30 (50.8%), dyslipemia 29 (49.2%) and 4 (6.9%) chronic renal disease. As mayor cardiovascular disease (3, 5.1%) suffered hearth disease and 2 (3.4%) an stroke. Four (6.8%) had chronic renal disease. 55.9% patients showed any degree of MAFLD with a median CAP of 265 [212–288] db/m. Two (3.4%) patients were diagnosed with liver fibrosis (kPa compatible with F3-F4). MAFLD was associated with obesity, time of hypercortisolism, curation, type 2 DM and hypertrigliceridemia.

Conclusions: The prevalence of MAFLD in patients with Cushing’s disease is high and higher than described in previous studies. Hepatic steatosis is associated with variables related with the metabolic syndrome and the curation of Cushing’ s disease. It is postulated that despite metabolic control, there is an increased risk of hepatic steatosis in uncured patients. A low percentage of liver fibrosis has been observed compared to the degree of fibrosis.